Answers are grounded in this paper and cite their sources.
Avapritinib and sunitinib are targeted therapies for advanced gastrointestinal stromal tumors (GISTs), but their efficacy varies by tumor genotype. Random effects meta-analyses pooled progression-free survival (PFS), time to progression (TTP), overall survival (OS), and overall response rate (ORR). Avapritinib (n = 5 ORR studies, n = 2 PFS studies) yielded a pooled ORR of 56% (95% CI: 23%–88%; I 2 = 98.6%) and PFS of 3.94 months (95% CI: 3.28–4.59; I 2 = 0.0%), reflecting rapid but transient responses in PDGFRA D842V-mutant disease. Sunitinib (n = 9 ORR studies, n = 7 PFS/OS studies) demonstrated a modest ORR of 18% (95% CI: 12%–25%; I 2 = 85.4%), PFS of 8.86 months (95% CI: 5.94–11.79; I 2 = 97.0%), and OS of 20.68 months (95% CI: 17.42–23.95; I 2 = 74.0%) in patients with KIT-mutant, imatinib-refractory disease. The GRADE assessment rated RCT evidence as high certainty but nonrandomized evidence as very low due to serious bias. Treatment outcomes for advanced GIST patients are fundamentally stratified by tumor genotype. Avapritinib delivers rapid cytoreduction in PDGFRA D842V-mutant disease despite its shorter durability, whereas sunitinib provides sustained disease stabilization in KIT-mutant disease. These findings mandate routine molecular profiling to guide genotype-informed therapy selection.
No takes yet. Share an insight, caveat, or question.
Machchhar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: